Can B Corp. Reports Growth of 45% to Company All-Time High $6.7 Million Annual Revenue
Led by Significant Increase in Duramed
Adjusted EBITDA Loss Decreased by 25% to $2.1 Million
HICKSVILLE, NY, April 19, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, today announced the Company’s financial results for the twelve months ended December 31, 2022.
Related news for (CANB)
- Can B Corp. Secures Ownership and Control of Two Cannabis Patents Valued at $122 Million and Potentially in Excess of $750 Million
- Can B Corp. Expects Nearly $500,000 Annual Savings With Successful Completion of Move of Pure Health Products From Lacey, WA to Colorado
- Can B Corp. Secures 1.8 Million Pounds of Biomass for Awarded Contract With One Bad Moon Rising
- Can B Corp. Completes Corporate Debt Restructuring to Position for Uplisting to National Securities Exchange